Denis N - Search Results

1

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.

Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F. Kosmider O, et al. Among authors: denis n. Oncogene. 2007 May 31;26(26):3904-8. doi: 10.1038/sj.onc.1210159. Epub 2006 Dec 18. Oncogene. 2007. PMID: 17173066

2

Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells.

Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F. Delva L, et al. Among authors: denis n. Oncogene. 2004 May 27;23(25):4389-99. doi: 10.1038/sj.onc.1207578. Oncogene. 2004. PMID: 15064749

3

Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F. Kosmider O, et al. Among authors: denis n. Cancer Cell. 2005 Dec;8(6):467-78. doi: 10.1016/j.ccr.2005.11.009. Cancer Cell. 2005. PMID: 16338660 Free article.

4

Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation.

Barnache S, Wendling F, Lacombe C, Denis N, Titeux M, Vainchenker W, Moreau-Gachelin F. Barnache S, et al. Among authors: denis n. Oncogene. 1998 Jun 11;16(23):2989-95. doi: 10.1038/sj.onc.1202095. Oncogene. 1998. PMID: 9662331

5

Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts.

Scolan EL, Wendling F, Barnache S, Denis N, Tulliez M, Vainchenker W, Moreau-Gachelin F. Scolan EL, et al. Among authors: denis n. Oncogene. 2001 Sep 6;20(39):5484-92. doi: 10.1038/sj.onc.1204708. Oncogene. 2001. PMID: 11571646

6

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin F. Barnache S, et al. Among authors: denis n. Oncogene. 2006 Mar 2;25(9):1420-3. doi: 10.1038/sj.onc.1209187. Oncogene. 2006. PMID: 16247441

7

Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression.

Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T, Moreau-Gachelin F. Le Scolan E, et al. Among authors: denis n. Blood. 2005 Sep 1;106(5):1808-16. doi: 10.1182/blood-2004-12-4832. Epub 2005 May 12. Blood. 2005. PMID: 15890687 Free article.

8

Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase.

Kosmider O, Buet D, Gallais I, Denis N, Moreau-Gachelin F. Kosmider O, et al. Among authors: denis n. PLoS One. 2009 May 28;4(5):e5721. doi: 10.1371/journal.pone.0005721. PLoS One. 2009. PMID: 19492092 Free PMC article.

9

Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.

Buet D, Gallais I, Lauret E, Denis N, Lombard B, Guillonneau F, Kosmider O, Loew D, Dusanter-Fourt I, Guillouf C, Mayeux P, Moreau-Gachelin F. Buet D, et al. Among authors: denis n. Blood. 2012 May 3;119(18):4228-41. doi: 10.1182/blood-2011-07-368316. Epub 2012 Mar 20. Blood. 2012. PMID: 22438255 Free article.

10

Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.

Selimoglu-Buet D, Gallais I, Denis N, Guillouf C, Moreau-Gachelin F. Selimoglu-Buet D, et al. Among authors: denis n. PLoS One. 2012;7(11):e49052. doi: 10.1371/journal.pone.0049052. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23145067 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters